DISPATCHNCT07936799
DISPATCH: Decreasing Intervention Using sFlt-1/PlGF Applied to Chronic Hypertension
StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Recruitment rate
Timeframe: At month 6
Protocol adherence in the reveal arm
Timeframe: At month 6
Secondary (15)
Time until delivery using a time-to-event analysis
Delivery with superimposed preeclampsia with severe features.
Rate of preterm birth at <35 weeks
Rate of preterm birth at <37 weeks
Maternal admission rate
Show 10 moreShow less
Maternal admission days
Maternal admission to the ICU
Severe maternal morbidity (with and without transfusion)
Gestational age at delivery
Birthweight
Birthweight percentile
Mode of delivery
Neonatal admission to the NICU
Days of neonatal admission to the NICU
Neonatal composite morbidity
Arms and interventions
Conceal armPlacebo comparator
The clinical team will be blinded to assay results and will manage as per their usual clinical protocol.
Reveal armExperimental
The clinical team will receive qualitative assay results normal (sFlt-1/PlGF \<40) or abnormal (sFlt-1/PlGF ³40)) and the ratio value and concentrations of PlGF and sFlt-1.
Diagnostic tests: sFlt/PlGF lab assay with change in clinical care, sFlt/PlGF without change in clinical care
Sites
1 site in 1 country
- University of California, San FranciscoSan Francisco, California, United States